EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 36 / No 5 (Mai 2020) Med Sci (Paris), 36 5 (2020) 515-520 References
Open Access
Issue
Med Sci (Paris)
Volume 36, Number 5, Mai 2020
Page(s) 515 - 520
Section Forum
DOI https://doi.org/10.1051/medsci/2020083
Published online 26 May 2020
  1. Moll S. Thrombophilia: clinical-practical aspects. J Thromb Thrombolysis 2015 ; 39 : 367–378. [CrossRef] [PubMed] [Google Scholar]
  2. Stevens SM. Role of thrombophilia testing: con. J Thromb Thrombolysis 2015 ; 39 : 379–391. [CrossRef] [PubMed] [Google Scholar]
  3. Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med 2017 ; 377 : 1177–1187. [Google Scholar]
  4. Collins FS. Medical and societal consequences of the human genome project. N Engl J Med 1999 ; 341 : 28–37. [Google Scholar]
  5. Lock M. Eclipse of the gene and the return of divination. Curr Anthropol 2005 ; 46 : S47–S71. [Google Scholar]
  6. La Latour B. science en action 1989 ; Paris: La Découverte [Google Scholar]
  7. Akrich M Callon M Latour B. Sociologie de la traduction 2006 ; Paris: Presses des Mines [Google Scholar]
  8. Gaudillière JP. Inventer la biomédecine : La France, l’Amérique et la production des savoirs du vivant (1945–1965) 2002 ; Paris: La Découverte [Google Scholar]
  9. Keating P, Cambrosio A. Biomedical platforms: realigning the normal and the pathological in late-twentieth-century medicine 2003 ; Cambridge, MA: MIT Press [CrossRef] [Google Scholar]
  10. Akrich M, Callon M, Latour B. À quoi tient le succès des innovations ? 1. L’art de l’intéressement. Gérer et comprendre. Annales des Mines 1988; 11 : 4–17. [Google Scholar]
  11. Akrich M, Callon M, Latour B. À quoi tient le succès des innovations ? 2. Le choix des porte-parole. Gérer et comprendre. Annales des Mines 1988; 12 : 14–29. [Google Scholar]
  12. Law J. Making a mess with method. In : Outhwaite W, Turner SP, eds. The sage. Handbook of social science methodology. London: Sage, 2007 : 595–606. [Google Scholar]
  13. Briggs JB. Recurring phlebitis of obscure origin. Bull Johns Hopkins Hospital 1905 ; 16 : 228. [Google Scholar]
  14. Egeberg O. Inherited antithrombin deficiency causing thrombophilia. Thromb Diath Haemorrh 1965 ; 13 : 516–530. [PubMed] [Google Scholar]
  15. De Stefano V, Finazzi G, Mannucci PM. Inherited thrombophilia: pathogenesis, clinical syndromes, and management. Blood 1996 ; 87 : 3531–3544. [Google Scholar]
  16. Bertina RM, Koeleman BP, Koster T, et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature 1994 ; 369 : 64–67. [Google Scholar]
  17. Poort SR, Rosendaal FR, Reitsma PH, et al. A common genetic variation in the 3’-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996 ; 88 : 3698–3703. [Google Scholar]
  18. Rosendaal FR. Venous thrombosis: a multicausal disease. Lancet 1999 ; 353 : 1167–1173. [CrossRef] [PubMed] [Google Scholar]
  19. Miletich JP, Prescott SM, White R, et al. Inherited predisposition to thrombosis. Cell 1993 ; 72 : 477–480. [CrossRef] [PubMed] [Google Scholar]
  20. Turrini M, Bourgain C. Genomic susceptibility in practice: the regulatory trajectory of non-rare thrombophilia (NRT) genetic tests in the clinical management of venous thrombo-embolism (VTE). Soc Sci Med 2020; 112903. doi: 10.1016/j.socscimed.2020.112903. [CrossRef] [PubMed] [Google Scholar]
  21. Segal JB, Brotman DJ, Emadi A, et al. Outcomes of genetic testing in adults with a history of venous thromboembolism. Agency Healthcare Research Quality (AHRQ). Publication 2009 ; 180 : 1–162. [Google Scholar]
  22. Bounameaux H, Factor V. Leiden paradox: risk of deep vein thrombosis but not of pulmonary embolism. Lancet 2000 ; 356 : 182–183. [CrossRef] [PubMed] [Google Scholar]
  23. Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010 ; 149 : 209–220. [CrossRef] [PubMed] [Google Scholar]
  24. Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed. American college of chest physicians evidence-based clinical practice guidelines. Chest 2012 ; 141 : e419S–e496S. [CrossRef] [PubMed] [Google Scholar]
  25. Rodger MA, Kahn SR, Wells PS, et al. Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy. CMAJ 2008 ; 179 : 417–426. [CrossRef] [PubMed] [Google Scholar]
  26. Eichinger S, Heinze G, Jandeck LM, et al. Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the vienna prediction model. Circulation 2010 ; 121 : 1630–1636. [CrossRef] [PubMed] [Google Scholar]
  27. Tosetto A, Iorio A, Marcucci M, et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012 ; 10 : 1019–1025. [CrossRef] [PubMed] [Google Scholar]
  28. Zöller B, Li X, Ohlsson H, et al. Family history of venous thromboembolism as a risk factor and genetic research tool. Thromb Haemost 2015 ; 114 : 890–900. [CrossRef] [PubMed] [Google Scholar]
  29. Haxaire C, Tromeur C, Couturaud F, et al. A qualitative study to appraise patients and family members perceptions, knowledge, and attitudes towards venous thromboembolism risk. PLoS One 2015 ; 1–13. [Google Scholar]
  30. Pernod G, Biron-Andreani C, Morange PE, et al. Recommandations pour la recherche de facteurs biologiques de risque dans le cadre de la maladie thromboembolique veineuse: applications cliniques. Sang Thrombose Vaisseaux 2009 ; 5–11. [Google Scholar]
  31. Alhenc-Gelas M, Aillaud MF, Delahousse B, et al. Facteurs biologiques de risque établis de maladie thromboembolique veineuse: état des connaissances et conséquences pour la pratique en biologie clinique. Sang Thrombose Vaisseaux 2009 ; 12–39. [Google Scholar]
  32. Bourgain C, Sabbagh A, Turrini M. Faut-il se fier aux tests génétiques ? Maladies, paternité, origines ethniques. Pour la Science 2019; 499. [Google Scholar]
  33. La Larat M. pilule est amère 2013 ; Paris: Stock [Google Scholar]
  34. Haute Autorité de Santé. Dépistage systématique de la thrombophilie avant une primo- prescription de contraception hormonale combinée. Recommandations en santé publique. Saint-Denis La Plaine : HAS, 2015 [Google Scholar]
  35. Bureau E, Hermann-Mesfen J. Les patients contemporains face à la démocratie sanitaire. Anthropologie Santé 2014; 8. [Google Scholar]
  36. Jordan B. 23andMe ou comment (très bien) valoriser ses clients. Med Sci (Paris) 2015 ; 31 : 447–449. [CrossRef] [EDP Sciences] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.